위더스제약

330350KOSDAQ

67.3 / 100

Reference Date: 2026-09-08

Financial Score22.0 / 40

News Sentiment21.3 / 25

Momentum14.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Rose 8.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Widus Pharmaceutical is a pharmaceutical company specializing in finished drug products for chronic diseases, focusing on cardiovascular, musculoskeletal, and digestive system treatments. Its key revenue driver is Atoren, a generic version of Lipitor, accounting for about 30% of total sales. The company is expanding its CMO business and enhancing market share through new product development.

Number of Employees

220people

Average Salary

52.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

20.09Industry Average 15.003.0Point

Higher than industry avg (caution)

PBR

1.02Industry Average 1.204.0Point

In line with industry avg

ROE

5.20Industry Average 8.002.5Point

Below industry avg

Debt Ratio

5.90Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼14.2% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 6.5% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
위더스제약, 종근당 탈모치료제 생산…10년·400억 규모 계약
위더스제약의 종근당과의 장기계약 체결로 탈모치료제 생산 능력 강화 및 수익 증대 기대.

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 7,560Won52-week high 11,94052-week low 6,010

1-month return5.0Point

1m +8.31% (rising)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14